NASDAQ:SCNX Scienture Q2 2026 Earnings Results & Report $3.36 -0.02 (-0.59%) Closing price 04:00 PM EasternExtended Trading$3.28 -0.07 (-2.23%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Scienture beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.07 versus the -$2.25 consensus estimate, while revenue of $0.34 million fell short of the $1.96 million estimate by $1.62 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call4:00 PM ET Scienture EPS ResultsActual EPS-$0.07Consensus EPS -$2.25Beat/MissBeat by +$2.18One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersScienture Revenue ResultsActual Revenue$0.34 millionExpected Revenue$1.96 millionBeat/MissMissed by -$1.62 millionYoY Revenue GrowthN/AUpcoming EarningsScienture's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Scienture Q2 2026 Earnings FAQ Did Scienture beat earnings estimates for Q2 2026? Scienture (NASDAQ:SCNX) reported earnings of -$0.07 per share for Q2 2026, beating the consensus estimate of -$2.25. The report was announced on Thursday, August 13, 2026. What was Scienture's revenue for Q2 2026? Scienture reported revenue of $0.34 million for Q2 2026, against a consensus estimate of $1.96 million. When is Scienture's next earnings date? Scienture's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scienture on the company's earnings history page. Scienture Earnings HeadlinesSCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential GrowthOctober 13 at 8:05 AM | globenewswire.comContrasting Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO)October 7, 2026 | americanbankingnews.comUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares still trade under 1 dollar. It just signed the largest transaction in its history, a new gold streaming deal backed by a strategic relationship with a major mining investment firm. A well-known sector financier has invested his own money and joins the CEO in an exclusive interview breaking down the full story.October 16 at 1:00 AM | Digest Publishing (Ad)SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and HospitalsOctober 5, 2026 | marketscreener.comMExclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptionsOctober 2, 2026 | msn.comSCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and HospitalsOctober 2, 2026 | globenewswire.comSee More Scienture Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email. Email Address About ScientureScienture (NASDAQ:SCNX) is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its areas of interest include neurological and psychiatric conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. The company’s portfolio includes prescription pharmaceutical products and product candidates intended to provide alternative delivery methods or other potential benefits compared with existing treatments. Scienture has identified ZolpiMist, an FDA-approved oral spray formulation of zolpidem tartrate for the short-term treatment of insomnia, as part of its commercial and development portfolio. Scienture primarily serves the U.S. pharmaceutical market and is focused on advancing, obtaining regulatory approval for, and commercializing therapies in its targeted CNS categories. The company’s operations and product strategy may evolve as it develops its pipeline and pursues commercialization opportunities.View Scienture ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
